Corticosteroid Therapy for Cardiac Sarcoidosis: A Systematic Review

Sadek, Mouhannad M.; Yung, Derek; Birnie, David H.; Beanlands, Rob; Nery, Pablo B.

doi:10.1016/j.cjca.2013.02.004

Cited by 237 publications

(180 citation statements)

References 28 publications

Supporting

Mentioning

156

Contrasting

Unclassified

Order By: Relevance

“…80,81 In a recent systematic review of 10 publications reporting outcomes after corticosteroid therapy, corticosteroids appeared to be beneficial for recovery of atrioventricular nodal function. 81 However, clear conclusions about other outcomes could not be drawn. The authors noted that ''there is a clear need for large multicentre prospective registries and trials in this patient population.''…”

Section: Management Of Cs Immunologic Therapymentioning

confidence: 99%

Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring

Chareonthaitawee

Beanlands

Chen

et al. 2017

Journal of Nuclear Cardiology

Self Cite

182

133

View full text Add to dashboard Cite

Section: Management Of Cs Immunologic Therapymentioning

confidence: 99%

Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring

Chareonthaitawee

Beanlands

Chen

et al. 2017

Journal of Nuclear Cardiology

Self Cite

182

133

View full text Add to dashboard Cite

“…In both studies the prognosis for CS patients was poorer versus those who had idiopathic complete AV block (3, 30). (33). The data summary for LV dysfunction from 73 patients, of whom 60 were treated with steroids and 13 were not, suggested that corticosteroid therapy is associated Azathioprine, cyclophosphamide, and infliximab are also sometimes used to treat CS (37).…”

Section: Screening For Cardiac Sarcoidosismentioning

confidence: 99%

“…The extent of LV dysfunction is commonly regarded as the most important predictor of survival (33). Several recent CMR studies have, however, raised the presence and extent of myocardial LGE as an even more important overall prognostic factor than LV function (6,44).…”

Section: Prognosismentioning

confidence: 99%

Clinical Management of Cardiac Sarcoidosis

Birnie

Nery

2017

Annals of Nuclear Cardiology

Self Cite

View full text Add to dashboard Cite

Approximately 5% of patients with sarcoidosis will have cardiac involvement clinically manifest as one or more of ventricular arrhythmias, conduction abnormalities and heart failure. Another 20% to 25% have clinically silent disease (asymptomatic cardiac involvement). There is a growing realisation that CS can be the first manifestation of sarcoidosis in any organ. In particular physicians should consider CS in patients with VT of unknown etiology and in patients aged <60 presenting with idiopathic advanced conduction system disease.Immunosuppression therapy (usually with corticosteroids) has been suggested for the treatment of clinically manifest CS despite modest data. Positron Emission Tomography (FDG-PET) imaging is often used to detect active disease and guide immunosuppression. The extent of left ventricular dysfunction seems to be the most important predictor of prognosis. Also the extent of LGE on CMR is emerging as an important prognostic factor. Patients with clinically manifest disease often need device therapy, usually with implantable cardioverter defibrillators. There are still much to be learned as regarding best practices in managing CS patients and multicenter research efforts are underway.

show abstract

“…Overall mortality ranges from 1% -6% [1]. When the heart is involved, the prognosis is generally less favorable, although, corticosteroids appear effective in improving AV conduction [5].…”

Section: Introductionmentioning

confidence: 99%

Sarcoidosis-Lymphoma Syndrome: A Spectrum of One Disease

Sharquie¹,

Al-Hayani²,

Abdulwahhab³

et al. 2015

JCDSA

View full text Add to dashboard Cite

Lymphoma might occur in association with sarcoidosis or sarcoidosis might be combined with lymphoma, in so called ("sarcoidosis-lymphoma syndrome"). This syndrome is well reported in medical literature. The question, which one starts before is difficult to answer, as in some cases sarcoidosis starts first then is followed by lymphoma but in other cases during the course of lymphoma sarcoid reaction might be seen. In the present report, we describe a case of 60 years male patient that is presented with a rash with classical sarcoid pathology that overtime changes into typical lymphoma ended with death.

show abstract

Corticosteroid Therapy for Cardiac Sarcoidosis: A Systematic Review

Cited by 237 publications

References 28 publications

Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring

Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring

Clinical Management of Cardiac Sarcoidosis

Sarcoidosis-Lymphoma Syndrome: A Spectrum of One Disease

Contact Info

Product

Resources

About